Northern Biologicals And Chemicals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-12-2024
- Paid Up Capital ₹ 0.50 M
as on 16-12-2024
- Company Age 47 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 5.88 M
as on 16-12-2024
- Revenue -34.80%
(FY 2022)
- Profit 39.45%
(FY 2022)
- Ebitda 63.15%
(FY 2022)
- Net Worth -53.88%
(FY 2022)
- Total Assets 1.42%
(FY 2022)
About Northern Biologicals And Chemicals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company has closed loans amounting to ₹5.88 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Venkata Penmetsa, Shobha Prasad, and Saeed Qureshi serve as directors at the Company.
- CIN/LLPIN
U74899DL1977PTC008753
- Company No.
008753
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Oct 1977
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Northern Biologicals And Chemicals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Saeed Qureshi  | Managing Director | 11-Oct-1977 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Venkata Penmetsa | Director | 11-Oct-1977 | Current |
| Shobha Prasad | Director | 18-Apr-1982 | Current |
Financial Performance and Corporate Structure Insights of Northern Biologicals And Chemicals.
Northern Biologicals And Chemicals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 34.8% decrease. The company also saw a substantial improvement in profitability, with a 39.45% increase in profit. The company's net worth observed a substantial decline by a decrease of 53.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Northern Biologicals And Chemicals?
In 2023, Northern Biologicals And Chemicals had a public holding of 53.44%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 25 Aug 2020 | ₹0.38 M | Satisfied |
Andhra Bank Creation Date: 09 Apr 2009 | ₹3.00 M | Satisfied |
Others Creation Date: 17 Aug 1985 | ₹2.50 M | Satisfied |
How Many Employees Work at Northern Biologicals And Chemicals?
Unlock and access historical data on people associated with Northern Biologicals And Chemicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Northern Biologicals And Chemicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Northern Biologicals And Chemicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
